FindTrial
Sign In

Kengrexal 50 mg powder for concentrate for solution for injection/infusion

DRUG4 trials

Sponsors

Azienda Ospedaliero-Universitaria Maggiore Della Carita, Ospedale San Raffaele S.r.l., Fondation A De Rothschild, Chiesi Farmaceutici S.p.A.

Conditions

Acute ischemic strokeAdult patients treated in VA ECMO/Impella for cardiogenic shock/cardiac arrest undergoing PCI. Given the high incidence of bleeding from conventional antithrombotic therapyCongenital Heart DiseaseST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI)the use of readily available and rapidly metabolized cangrelor should result in adequate efficacy and increased safety. Patients will receive scoagulation with bivalirudin (target apt 55-70 seconds) and cangrelor with starting dose 0.125 mcg/kg/min and adjusted with step +/- 0.125 mcg/kg/min.

Phase 2

Efficacy and Safety of cangrelor on top of anticoagUlation in patients with myocaRdial infarction related cardiogenic shock/cardiac arrest receiVIng VA-ECMO and/or Impella support – a phase 2, single arm, single center trial
RecruitingCTIS2024-512829-81-00
Ospedale San Raffaele S.r.l.Adult patients treated in VA ECMO/Impella for cardiogenic shock/cardiac arrest undergoing PCI. Given the high incidence of bleeding from conventional antithrombotic therapy, the use of readily available and rapidly metabolized cangrelor should result in adequate efficacy and increased safety. Patients will receive scoagulation with bivalirudin (target apt 55-70 seconds) and cangrelor with starting dose 0.125 mcg/kg/min and adjusted with step +/- 0.125 mcg/kg/min.
Start: 2024-04-10Target: 50Updated: 2024-12-06

Phase 3

Reperfusion with P2Y12 inhibitors in addition to mechanical thrombectomy for perfusion imaging selected acute stroke patients : a multicentric randomized controlled trial.
Not yet recruitingCTIS2024-516163-88-00
Fondation A De RothschildAcute ischemic stroke
Target: 368Updated: 2025-10-02
A prospective, open-label, non-randomized, multicentre trial to assess the safety and PD of Cangrelor as procedural platelet inhibitor in paediatric subjects from birth to <18 years of age undergoing diagnostic and/or therapeutic percutaneous vascular procedures for management of congenital heart disease
Not yet recruitingCTIS2025-523109-14-00
Chiesi Farmaceutici S.p.A.Congenital Heart Disease
Target: 40Updated: 2026-06-09

Phase 4

PhARMacodynamics of earlY versus Delayed Administration of TIcagrelor during CAngrelor infusion in patients with acute ST-segment elevation Myocardial Infarction: a randomized superiority study
Not yet recruitingCTIS2024-511944-18-01
Azienda Ospedaliero-Universitaria Maggiore Della CaritaST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI)
Target: 50Updated: 2024-08-13